Local News

• Array BioPharma accelerates partnering activities and scales back discovery research  Array BioPharma announced plans to accelerate partnering initiatives and scale back discovery research spending over the next 24 months to help ensure sustainable growth through the current uncertain capital market conditions.
  Array BioPharma Inc. January 09, 2009  
• Array BioPharma initiates Phase 1 clinical trial for MEK inhibitor ARRY-300  Array BioPharma has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor.
  Array BioPharma Inc. January 09, 2009  
• Covidien wins 2008 Zenith Award  Covidien announced that it has received the prestigious American Association for Respiratory Care (AARC) Zenith Award for 2008. Established in 1989, the Zenith Award recognizes respiratory care product and service providers who offer exemplary service to the respiratory care community.
  Covidien January 09, 2009  
• Spectranetics reports preliminary revenue for fourth quarter and full-year 2008  Spectranetics reported preliminary revenue for the quarter and year ended December 31, 2008. Preliminary revenue for the fourth quarter of 2008 was $26.6 million, up 11% compared with revenue of $23.9 million for the fourth quarter of 2007.
  Spectranetics Corporation January 08, 2009  
• Howard Feldman joins Bristol-Myers Squibb as vice president and therapeutic area head  Bristol-Myers Squibb announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area head, Global Clinical Research, Neuroscience.
  Bristol-Myers Squibb Company January 08, 2009  
• Liquidia, Abbott team up to target cancer  One of the biggest challenges of cancer treatment is delivering drugs in a way that kills the bad cells without doing too much damage to healthy cells. The CEO of Liquidia Technologies hopes that a deal announced between his company and Abbott Laboratories will help to address that problem.
  Triangle Business Journal January 07, 2009  Jeff Drew
• Positive step for drug from engineered goat  In a surprise move, it seems likely the first genetically engineered animal approved for commercial use won't be a fast-growing salmon, as was expected, but a goat that produces an anti-clotting drug in its milk.
  USATODAY January 07, 2009  Elizabeth Weise
• FDA issues a Complete Response Letter for Lilly's olanzapine LAI  Eli Lilly and Company announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.
  Eli Lilly and Company January 07, 2009  
• Health care could nab $100B payday  The $775 billion economic stimulus plan being cobbled together by President-elect Barack Obama and congressional Democrats could pump more than $100 billion into the health care sector, modernizing its delivery system and providing care to those who lost their health insurance.
  Politico January 07, 2009  Chris Frates
• Monsanto takes major step toward launch of world's first drought-tolerant corn product  As farmers around the world search for innovative new technologies to help them produce more with fewer resources, Monsanto Company announced that it is a major step closer to delivering the world's first-ever drought-tolerant corn product to farmers.
  Monsanto Company January 07, 2009  

   (next 10 articles)